Drug Type Synthetic peptide |
Synonyms Thymalfaxin, Thymosin alpha1 (human), Thymosin-α-1 + [8] |
Target |
Mechanism 5-HT6 receptor antagonists(Serotonin 6 (5-HT6) receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date CN (01 Jan 1996), |
RegulationOrphan Drug (US) |
Molecular FormulaC129H215N33O55 |
InChIKeyNZVYCXVTEHPMHE-ZSUJOUNUSA-N |
CAS Registry62304-98-7 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hepatitis B, Chronic | CN | 01 Jan 1996 | |
Hepatitis B | - | - | - |
Hepatitis C | - | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | CN | 01 Apr 2023 | |
Kidney Failure, Chronic | Discovery | IT | 01 Nov 2009 | |
Hepatitis C, Chronic | Discovery | GR | 01 Dec 2004 | |
Hepatitis C, Chronic | Discovery | FR | 01 Dec 2004 | |
Hepatitis C, Chronic | Discovery | IT | 01 Dec 2004 | |
Hepatitis C, Chronic | Discovery | ES | 01 Dec 2004 | |
Hepatitis C, Chronic | Discovery | DE | 01 Dec 2004 | |
Hepatocellular Carcinoma | Discovery | US | 28 Apr 2004 |
Phase 2 | Metastatic Solid Tumor T lymphocyte count | 6 | PRaG regimen + Thymalfasin | (cuvvzosolo) = upmvmgjddj kdrqsvrtdd (odhopuiwzw ) View more | Positive | 01 Oct 2024 | |
Phase 2 | - | (rkuxcnvnht) = faknqodett pfhcuhczfi (hlvtfarfxo ) View more | Positive | 24 May 2024 | |||
NCT04963712 (Pubmed) Manual | Early Phase 1 | HIV Infections PD-1 | TIM-3 | sjTREC | 20 | Thymosin α1 1.6 mg + antiretroviral therapy | tzfumdminy(pmpizpzwet) = nmyspxepbf sqgraojtxd (wsxfenflve ) View more | Positive | 17 Jan 2024 |
Thymosin α1 1.6 mg + antiretroviral therapy (baseline) | tzfumdminy(pmpizpzwet) = uhayqfzdcs sqgraojtxd (wsxfenflve ) View more | ||||||
Phase 2 | 49 | (fxricjodbd) = Nine serious adverse events among treated patients were deemed not related to Tα1. jmzwvdaeyk (zyktquhihx ) View more | Positive | 03 Sep 2022 | |||
(Standard of care) | |||||||
Phase 4 | - | 160 | nnzwihiehq(qinnuckxvq) = 14 (8.8%) had acute kidney failure jomtunlmuj (vpfjhiwwhw ) View more | - | 14 Oct 2011 | ||
Not Applicable | 18 | (Group 1) | (afisjsrmrs) = efehvbylyu znywqcciea (bniwdrgjta ) | - | 01 Jun 2005 | ||
(Group 2) | (udclgzvjlf) = xcmajivxuf xzjspsmjgl (etzppzrigx ) |